In Response to: 'Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy?' by Ostler et al. and 'Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy - No' by Macbeth and Hughes-Davies

Affiliations

¹ Edinburgh Cancer Centre, Edinburgh, UK; Edinburgh Cancer Research UK Centre, Edinburgh, UK. Electronic address: iain.phillips@nhslothian.scot.nhs.uk.
² Department of Radiation Oncology, BC Cancer - Centre for the North, Prince George, British Columbia, Canada.
³ Department of Oncology, London Health Sciences Centre, London, Ontario, Canada.
⁴ Edinburgh Cancer Centre, Edinburgh, UK; Edinburgh Cancer Research UK Centre, Edinburgh, UK.

Comment

I Phillips et al. Clin Oncol (R Coll Radiol). 2022 Apr.

. 2022 Apr;34(4):e169-e170.

doi: 10.1016/j.clon.2022.01.041. Epub 2022 Feb 8.

¹ Edinburgh Cancer Centre, Edinburgh, UK; Edinburgh Cancer Research UK Centre, Edinburgh, UK. Electronic address: iain.phillips@nhslothian.scot.nhs.uk.
² Department of Radiation Oncology, BC Cancer - Centre for the North, Prince George, British Columbia, Canada.
³ Department of Oncology, London Health Sciences Centre, London, Ontario, Canada.
⁴ Edinburgh Cancer Centre, Edinburgh, UK; Edinburgh Cancer Research UK Centre, Edinburgh, UK.

No abstract available

Comment on

Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy - No.
Macbeth F, Hughes-Davies L. Macbeth F, et al. Clin Oncol (R Coll Radiol). 2021 Dec;33(12):749-750. doi: 10.1016/j.clon.2021.06.005. Epub 2021 Jul 1. Clin Oncol (R Coll Radiol). 2021. PMID: 34218999 No abstract available.
Should We be Offering Our Patients With Oligometastases Stereotactic Ablative Body Radiotherapy?
Ostler P, Hoskin P, Martin A. Ostler P, et al. Clin Oncol (R Coll Radiol). 2021 Dec;33(12):747-748. doi: 10.1016/j.clon.2021.09.016. Epub 2021 Oct 9. Clin Oncol (R Coll Radiol). 2021. PMID: 34642067 No abstract available.